What is the recommended treatment for Clostridioides difficile infection?

Treatment of Clostridioides difficile Infection

For initial C. difficile infection, fidaxomicin 200 mg twice daily for 10 days is the preferred first-line treatment, with vancomycin 125 mg four times daily for 10 days as an acceptable alternative. 1

Initial Episode Treatment Algorithm

Preferred Regimen

• Fidaxomicin 200 mg orally twice daily for 10 days 1
  • Reduces recurrence risk compared to vancomycin 2
  • Real-world data shows 63% reduction in composite outcome of clinical failure, 30-day relapse, or CDI-related death 2

Alternative Regimen

• Vancomycin 125 mg orally four times daily for 10 days 1
  • Remains acceptable when fidaxomicin unavailable or cost-prohibitive
  • Metronidazole is no longer recommended when vancomycin or fidaxomicin are available 3

Only if Fidaxomicin and Vancomycin Unavailable (Nonsevere CDI)

• Metronidazole 500 mg orally three times daily for 10-14 days 1
  • Nonsevere defined as: WBC ≤15,000 cells/μL AND serum creatinine <1.5 mg/dL 1

Severe/Fulminant CDI

For fulminant CDI (hypotension/shock, ileus, or megacolon), use high-dose vancomycin 500 mg orally or via nasogastric tube four times daily PLUS intravenous metronidazole 500 mg every 8 hours. 1

• If ileus present: Add rectal vancomycin instillation (500 mg in 500 mL saline as enema four times daily) 4
• Early surgical consultation is critical 5

First Recurrence

Fidaxomicin 200 mg twice daily for 10 days (standard or extended regimen: 5 days twice daily, then once every other day for 20 days) is preferred. 1

Alternatives for First Recurrence:

• Vancomycin tapered and pulsed regimen: 125 mg four times daily for 10-14 days, then twice daily for 7 days, then once daily for 7 days, then every 2-3 days for 2-8 weeks 1
• Standard vancomycin 125 mg four times daily for 10 days (particularly if metronidazole was used initially) 1

Adjunctive Therapy Consideration:

• Bezlotoxumab 10 mg/kg IV once during antibiotic administration for patients at high risk of recurrence 1
  • High-risk factors: age >65 years, immunocompromised, severe CDI on presentation
  • Caution in congestive heart failure patients - reserve for when benefit outweighs risk 1
  • Limited data when combined with fidaxomicin 1

Second or Subsequent Recurrence

After at least 2 recurrences (3 total CDI episodes), fecal microbiota transplantation (FMT) should be offered. 1

Treatment Options (in order of preference):

1. Fidaxomicin 200 mg twice daily for 10 days OR extended regimen 1
2. Vancomycin tapered and pulsed regimen 1
3. Vancomycin 125 mg four times daily for 10 days followed by rifaximin 400 mg three times daily for 20 days 1
4. Fecal microbiota transplantation 1
5. Bezlotoxumab as adjunctive therapy 1

Critical Safety Alerts

FDA has issued multiple safety alerts regarding FMT since 2019 1:

• Transmission of pathogenic E. coli from donor to recipients (some deaths reported)
• Potential SARS-CoV-2 transmission risk
• Appropriate donor and specimen screening is mandatory 1

Key Clinical Pearls

• Stop precipitating antibiotics immediately when CDI diagnosed 4
• Recent evidence shows vancomycin pulse-and-taper (4 weeks) has 99% probability of superiority over standard 2-week pulse for preventing early recurrence at day 38 6
• Discontinue chronic proton pump inhibitors - associated with increased CDI risk, particularly during pandemic period 7
• Treatment response may require 3-5 days; escalation can be considered sooner based on severity 4
• The 2021 IDSA/SHEA guidelines represent a paradigm shift away from metronidazole as first-line therapy 1, 3